Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 31:10:148.
doi: 10.1186/1471-2350-10-148.

Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data

Affiliations

Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data

Audrey Sabbagh et al. BMC Med Genet. .

Abstract

Background: Genetically determined differences in N-acetylation capacity have proved to be important determinants of both the effectiveness of therapeutic response and the development of adverse drug reactions and toxicity during drug treatment. NAT2PRED is a web-server that allows a fast determination of NAT2 acetylation phenotype from genotype data without taking the extra step of reconstructing haplotypes for each individual (publicly available at http://nat2pred.rit.albany.edu). However, the classification accuracy of NAT2PRED needs to be assessed before its application can be advocated at a large scale.

Methods: The ability of NAT2PRED to classify individuals according to their acetylation status (slow, intermediate and rapid acetylators) was evaluated in a worldwide dataset composed of 56 population samples (8,489 individuals) from four continental regions.

Results: NAT2PRED correctly identified slow acetylators with a sensitivity above 99% for all populations outside sub-Saharan Africa. Nevertheless, NAT2PRED showed a poor ability to distinguish between intermediate and rapid acetylators, with a classification error rate reaching up to 10% in the non-African samples.

Conclusion: NAT2PRED is an excellent tool to infer the individual acetylation status from NAT2 genotype data when the main interest is to distinguish slow acetylators from the others. This should facilitate the determination of the individual acetylation status in routine clinical practice and lead to better monitoring of risks associated with cancer and adverse drug reactions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification error rates of NAT2PRED in the 56 worldwide samples. The classification accuracy of NAT2PRED was evaluated using either three phenotypic classes (slow, intermediate and rapid acetylators; hatched area) or two phenotypic classes (slow and other acetylators; black area) for the acetylation status. Single populations are reported on the left side of the plot, with sample sizes (number of individuals) in brackets. Geographic areas are indicated on the right side, as follows: SSAFRICA, sub-Saharan Africa; EUROPE/NORTH AFRICA, Europe and North Africa; CSASIA, Central and South Asia; EAST ASIA, East Asia; AME, America. The assignment of populations to one of the five world regions was based on the origin of the population, in effect ignoring the past 1,000 years of known human migration (e.g., people of European descent in the United States were assigned to Europe).

Similar articles

Cited by

References

    1. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics. 2002;3(3):349–366. doi: 10.1517/14622416.3.3.349. - DOI - PubMed
    1. Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr Drug Metab. 2008;9(6):532–537. doi: 10.2174/138920008784892038. - DOI - PubMed
    1. Agúndez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9(6):520–531. doi: 10.2174/138920008784892083. - DOI - PubMed
    1. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–659. doi: 10.1016/S0140-6736(05)67137-1. - DOI - PMC - PubMed
    1. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;25(11):1649–1658. doi: 10.1038/sj.onc.1209374. - DOI - PMC - PubMed

Substances

LinkOut - more resources